2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 217-219
Technology and Procedures, Bioinformatics, Treatment Considerations, Biological Therapies, Gene Therapy, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Workforce, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Study Population, Human, Adult, Pediatric
PAPER

1074 Lifetime inhibitor incidence with emicizumab-only prophylaxis and the cost-effectiveness of time-definite factor VIII exposure added to emicizumab prophylaxis in previously untreated patients (PUPs) with severe hemophilia A

Sam Hirniak, PhD, Satoko Ito, MD, PhD2, Manraj Sra, MD3, Ding Quan Ng, PhD4, Adam Cuker, MD, MS5, Stacy Croteau, MD6, George Goshua, MD, SM7
1 Yale Cancer Center & Yale School of Medicine, New Haven, United States
2 Yale Cancer Center & Yale School of Medicine, New Haven, United States
3 Yale Cancer Center & Yale School of Medicine, New Haven, United States
4 Yale Cancer Center & Yale School of Medicine, New Haven, United States
5 University of Pennsylvania, Philadelphia, United States
6 Boston Children's Cancer and Blood Disorders Center, Boston, United States
7 Yale Cancer Center & Yale School of Medicine, New Haven, United States

Introduction: Previously untreated patients (PUPs) living with severe hemophilia A (HA) face the highest risk of factor VIII (FVIII) inhibitor development within the first 20 exposure days (ED), plateauing after 75 ED. FVIII exposure during immunological danger periods (bleeding, surgery) further increases inhibitor development risk. Emicizumab revolutionized hemophilia prophylaxis for PUPs with subcutaneous bleed prevention with earlier initiation. Use of emicizumab delays children’s exposure to exogenous FVIII which occurs primarily at immunological danger periods. The impact of this altered timeframe and intensity of FVIII exposure on lifetime incidence of inhibitors remains unknown. Emicizumab with time-limited FVIII exposure through 75 ED to promote primary immune tolerance and reduce long-term inhibitor development may be cost-effective. To address these knowledge gaps, we sought to 1) project the lifetime incidence of FVIII inhibitors on emicizumab prophylaxis and 2) evaluate the cost-effectiveness of time-limited (first 75 ED) factor VIII with emicizumab versus emicizumab alone.

Methods: We developed a lifetime microsimulation to evaluate inhibitor incidence across three prophylactic strategies for PUPs with severe HA starting at 6 months of age: 1) standard half-life (SHL) FVIII, 2) emicizumab, and 3) time-limited SHL FVIII with emicizumab, followed by emicizumab alone. Patients were at risk of bleeding events, surgical procedures, inhibitor development, and death. Clinical efficacy and bleeding rates were based on randomized HAVEN3 trial data and the observational International Immune Tolerance Study. Cumulative FVIII ED were tracked to estimate inhibitor development using data from the prospective PedNet cohort, with increased inhibitor risk during danger periods informed from the largest prospective inhibitor risk factor study. Patients developing inhibitors were assumed to undergo immune tolerance induction (ITI) therapy while receiving prophylaxis with successful responders resuming their original prophylaxis while nonresponders remained on emicizumab with bypassing agents used for breakthrough bleeds and surgeries. Health-related quality of life was measured in quality-adjusted life years (QALYs) and quantified using severe HA-specific age-dependent utility values, with disutilities for injections, bleeding events, complications, and ITI. Costs were sourced from the Centers for Medicare & Medicaid Services and published literature. The primary outcome was inhibitor incidence per strategy. The secondary outcome was the incremental net monetary benefit (iNMB) of time-limited FVIII with emicizumab prophylaxis, conducted from the US health system perspective and evaluated across all accepted US willingness-to-pay (WTP) thresholds with a base-case WTP of $120,000/QALY. We concluded with sensitivity analyses for sets of 3,000 patients each across 1,000 simultaneous parameter draws (i.e., 3 million patients).

Results: Over a lifetime horizon, patients receiving FVIII-only prophylaxis accumulated a mean of 9,837 FVIII ED, compared with 188 ED on emicizumab-only prophylaxis. The projected lifetime inhibitor incidences with FVIII-only, emicizumab-only, and time-limited FVIII with emicizumab prophylaxis were 30.0% [95% CI, 28.2-31.9], 43.1% [95% CI, 41.0-45.4], and 29.3% [95% CI, 27.5-31.1], respectively. Inhibitor development with emicizumab-only prophylaxis was delayed by 7.9 years compared with FVIII-only prophylaxis. In the base case, 1) FVIII-only, 2) emicizumab-only and 3) time-limited FVIII with emicizumab accrued 24.65, 26.42 and 26.42 QALYs, at discounted costs of $14.1, $17.2, and $16.4 million, respectively. The per-patient iNMB was $876,000 (95% credible interval, $487,000-1,284,000), favoring time-limited FVIII with emicizumab over emicizumab-only prophylaxis. In deterministic sensitivity analyses, price of FVIII concentrate and hazard ratios for inhibitor development during danger periods had the greatest impact on the results, although the conclusion did not change. Time-limited FVIII added to emicizumab was favored in 100% of Monte Carlo iterations over emicizumab-only prophylaxis.

Conclusion: Emicizumab-only prophylaxis for PUPs delays FVIII inhibitor development and results in higher cumulative inhibitor incidence. Early time-limited FVIII exposure with emicizumab for PUPs may reduce the lifetime burden of inhibitor development compared with emicizumab alone, reducing overall healthcare costs.

Sam Hirniak, PhD: No relevant conflicts of interest to declare.